| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 09/20/2001 | CA2402250A1 Immunomodulatory polynucleotide sequences for use in suppressing hepatitis virus infection |
| 09/20/2001 | CA2402248A1 Polypeptides and nucleic acids encoding same |
| 09/20/2001 | CA2402041A1 Antisense oligonucleotides of the human chk1 gene and uses thereof |
| 09/20/2001 | CA2401273A1 Il-17 receptor like molecules and uses thereof |
| 09/20/2001 | CA2400238A1 Human nim1 kinase |
| 09/20/2001 | CA2373110A1 Production of chimeric capsid vectors |
| 09/19/2001 | EP1134286A2 Adamts polypeptides, nucleic acids encoding them, and uses thereof |
| 09/19/2001 | EP1133997A2 Treatment of immune diseases with beta-interferon |
| 09/19/2001 | EP1133994A1 A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA" |
| 09/19/2001 | EP1133993A1 Substances for the treatment of spinal muscular atrophy |
| 09/19/2001 | EP1133988A1 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 09/19/2001 | EP1133695A1 Immunostimulatory dna |
| 09/19/2001 | EP1133575A2 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2 |
| 09/19/2001 | EP1133567A1 Methioninase gene therapy for tumor treatment |
| 09/19/2001 | EP1133558A1 Compositions and methods for increasing bone mineralization |
| 09/19/2001 | EP1133552A2 Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
| 09/19/2001 | EP1133517A1 INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN |
| 09/19/2001 | EP1133516A1 Chromosome 17p-linked prostate cancer susceptibility gene |
| 09/19/2001 | EP1133318A1 Supramolecular complexes containing therapeutic agents |
| 09/19/2001 | EP1133316A1 Formulation of adenovirus for gene therapy |
| 09/19/2001 | EP1133311A2 INFLUENCING OF ANGIGENESIS USING CD66a |
| 09/19/2001 | EP0948522A4 Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines |
| 09/19/2001 | EP0862634B1 Pharmaceutical composition for treating papillomavirus tumours and infection |
| 09/19/2001 | EP0593755B1 Defective recombinant adenoviruses expressing cytokines for use in antitumoral treatment |
| 09/19/2001 | CN1313873A Polyester analogus of poly-L-Lysine as a soluble, biodegradable gene delivery carrier |
| 09/19/2001 | CN1313385A Process for preparing genetically engineered efficient medicine target-introduced to human liver cells |
| 09/19/2001 | CN1313130A Application of RIZ gene in detecting and treating tumor showing MSI positive |
| 09/18/2001 | US6291663 TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma |
| 09/18/2001 | US6291437 The protein/nucleic acid compositions are administered in an amount capable of inducing cell mediated immunity and/or antibody response in the subject. |
| 09/18/2001 | US6291423 Lipid complexes for transferring at least a therapeutically active substance, in particular a polynucleotide into a target cell and use in gene therapy |
| 09/18/2001 | US6291246 DNA virus vectors and methods for their preparation |
| 09/18/2001 | US6291243 Expression vectors for the insertion of genetic material into cells; for use in gene therapy |
| 09/18/2001 | US6291240 Cells or tissues with increased protein factors and methods of making and using same |
| 09/18/2001 | US6291237 Cancer diagnosis and therapy based on mutations in TGF-β receptors |
| 09/18/2001 | US6291226 Adenovirus mutants with deleted protease gene |
| 09/18/2001 | US6291211 Expressing heterologous polypeptides in cells; incubate cells with expression vectors, transform cells, express heterologous polypeptide |
| 09/18/2001 | US6291195 Generating ligands which bind preferential human receptors; incubate cells expressing preferential binding protein with modulator, detect adjustment in binding activity |
| 09/18/2001 | US6291175 Methods for treating a neurological disease by determining BCHE genotype |
| 09/18/2001 | US6290969 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 09/18/2001 | US6290949 Used to treat restenosis, especially when incident to injury by angioplasty. |
| 09/15/2001 | WO2001068859A2 Il-17 receptor like molecules and uses thereof |
| 09/15/2001 | CA2403370A1 Il-17 receptor like molecules and uses thereof |
| 09/13/2001 | WO2001066781A1 Conditional immortalisation of cells |
| 09/13/2001 | WO2001066772A2 Heparinase iii and uses thereof |
| 09/13/2001 | WO2001066760A2 Novel human kinase interacting protein and polynucleotides encoding the same |
| 09/13/2001 | WO2001066749A2 A member of the lectin superfamily |
| 09/13/2001 | WO2001066746A2 G-protein coupled receptor related polypeptides |
| 09/13/2001 | WO2001066745A2 Presenilin/crk binding polypeptides (pcbp) and methods of use thereof |
| 09/13/2001 | WO2001066731A1 A novel polypeptide-human zinc finger protein 32 and the polynucleotide encoding said polypeptide |
| 09/13/2001 | WO2001066722A1 Immune system-related polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066716A1 Polypeptide having phosphodiesterase activity |
| 09/13/2001 | WO2001066706A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066699A2 P27 and p21 in gene therapies |
| 09/13/2001 | WO2001066597A2 Inflammation-related gene |
| 09/13/2001 | WO2001066596A2 Human fgf-23 gene and gene expression products |
| 09/13/2001 | WO2001066595A2 Human fgf-23 gene and gene expression products |
| 09/13/2001 | WO2001066584A1 A novel polypeptide, human pax protein 9 and the polynucleotide encoding thereof |
| 09/13/2001 | WO2001066572A2 Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof |
| 09/13/2001 | WO2001066566A2 Rotavirus pseudoviral particles and use thereof for vectorizing proteins or nucleic acids |
| 09/13/2001 | WO2001066559A1 INHIBITION OF Tp12 TO TREAT INFLAMMATORY DISEASES |
| 09/13/2001 | WO2001066557A1 Adam polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066151A1 Methods and kits for locally administering an active agent to an interstitial space of a host |
| 09/13/2001 | WO2001066150A2 Highly efficient gene transfer into human repopulating stem cel ls by rd114 pseudotyped retroviral vector particles |
| 09/13/2001 | WO2001066149A2 Nucleic acid formulations for gene delivery and methods of use |
| 09/13/2001 | WO2001066148A1 A method of sensitising endothelial cells to prodrugs |
| 09/13/2001 | WO2001066140A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | WO2001066137A1 Adenovirus formulations |
| 09/13/2001 | WO2001066129A1 Substances for the treatment of spinal muscular atrophy |
| 09/13/2001 | WO2001066107A2 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | WO2001066085A2 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 09/13/2001 | WO2001065911A2 Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| 09/13/2001 | WO2001029178A3 Epo primary response gene 1, eprg1 |
| 09/13/2001 | WO2001029062A3 Method for modulation of cell phenotype |
| 09/13/2001 | WO2001028576A3 NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY |
| 09/13/2001 | WO2001027256A3 Chimeric transcriptional regulatory element and methods for prostate-targeted gene expression |
| 09/13/2001 | WO2001016288A3 Dna encoding the human serine protease c-e |
| 09/13/2001 | WO2001005480A3 Chemokine binding protein of gammaherpesvirus 68 and methods of use therefor |
| 09/13/2001 | WO2001004282A3 Replication-competent anti-cancer vectors |
| 09/13/2001 | WO2001003744A3 Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of the c, d or v genes |
| 09/13/2001 | WO2000041731A9 Reverse gene therapy |
| 09/13/2001 | WO2000039347A9 A tumor suppressor protein involved in death signaling, and diagnostics, therapeutics, and screening based on this protein |
| 09/13/2001 | WO2000034780A8 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3? |
| 09/13/2001 | US20010021772 Vascular endothelial growth factor |
| 09/13/2001 | US20010021701 Contacting the ductal epithelium of the exocrine gland with epithelium destroying agents such as ethanol and vaccinia virus |
| 09/13/2001 | US20010021700 Vectors, host cells, antibodies, and recombinant and synthetic methods for producing polynucleotides and the polypeptides they encode |
| 09/13/2001 | US20010021699 Therapeutic and drug screening methods for the treatment and prevention of neuronal disease |
| 09/13/2001 | US20010021526 Immortal rho degrees cell line; undifferentiated cells for drug screening; alzheimers, huntington's disease, myoclonic epilepsy lactic acidosis and stroke (MELAS); myoclonic epilepsy ragged red fiber (MERRF) |
| 09/13/2001 | US20010021524 Viral-mediated gene transfer system |
| 09/13/2001 | US20010021516 An isolated nucleic acid molecule comprising a polynucleotide having nucleotide sequence atleast 95% identical to a sequence selected from a nucleotide sequence encoding a TRID polypeptide having specific amino acid sequence |
| 09/13/2001 | US20010021507 Renal nuclear matrix protein able to differentiate cancerous renal cell from normal renal cells; useful for diagnosis and producing treatment for cell proliferative disorders of the kidney |
| 09/13/2001 | US20010021395 Mixture of nucleic acid and anticancer agent |
| 09/13/2001 | US20010021384 Administering vaccine |
| 09/13/2001 | CA2799545A1 Adenovirus formulations |
| 09/13/2001 | CA2403029A1 Rotavirus pseudoviral particles and use thereof for vectorizing proteins or nucleic acids |
| 09/13/2001 | CA2402602A1 Polynucleotides which are of nature b2/d+ a- and which are isolated from e. coli, and biological uses of these polynucleotides and of their polypeptides |
| 09/13/2001 | CA2402509A1 Methods and kits for locally administering an active agent to an interstitial space of a host |
| 09/13/2001 | CA2402027A1 A method of sensitising endothelial cells to prodrugs |
| 09/13/2001 | CA2401971A1 Novel human kinase interacting protein and polynucleotides encoding the same |
| 09/13/2001 | CA2401549A1 G-protein coupled receptor related polypeptides |
| 09/13/2001 | CA2401327A1 Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use |